Pulmatrix, Inc. (PULM)
| Market Cap | 5.73M -67.4% |
| Revenue (ttm) | n/a |
| Net Income | -4.03M |
| EPS | -1.10 |
| Shares Out | 3.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 130,744 |
| Open | 1.400 |
| Previous Close | 1.430 |
| Day's Range | 1.376 - 1.610 |
| 52-Week Range | 1.160 - 5.080 |
| Beta | 1.93 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 3, 2026 |
About PULM
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in ch... [Read more]
Financial Performance
Financial StatementsNews
Pulmatrix Proxy statement: Proxy filing
Pulmatrix filed a proxy statement on October 7, 2026, providing details for shareholder voting and corporate governance matters.
Pulmatrix Registration statement: Registration filing
Pulmatrix filed a registration statement on October 5, 2026, providing details about a securities offering with the SEC.
Pulmatrix Proxy statement: Proxy filing
Pulmatrix filed a proxy statement on September 25, 2026, providing details for shareholder voting and corporate governance matters.
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria
Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicine Eos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-hum...
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger
Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX FRAMINGHAM, Mass., Aug. 13, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmac...
Pulmatrix Earnings release: Q2 2026
Pulmatrix released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Pulmatrix Quarterly report: Q2 2026
Pulmatrix has published its Q2 2026 quarterly earnings report on August 13, 2026.
Pulmatrix Registration statement: Registration filing
Pulmatrix filed a registration statement on August 7, 2026, providing details about a securities offering with the SEC.
Pulmatrix Registration statement: Registration filing
Pulmatrix filed a registration statement on June 4, 2026, providing details about a securities offering with the SEC.
Pulmatrix files to sell 490,910 shares of common stock for holders
06:13 EDT Pulmatrix (PULM) files to sell 490,910 shares of common stock for holders
Pulmatrix Announces First Quarter 2026 Financial Results
Announced merger agreement with Eos SENOLYTIX in March Closed private placement of preferred stock FRAMINGHAM, Mass., May 15, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasda...
Pulmatrix Quarterly report: Q1 2026
Pulmatrix has published its Q1 2026 quarterly earnings report on May 15, 2026.
Pulmatrix Earnings release: Q1 2026
Pulmatrix released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
Series B Preferred Stock investment made in Pulmatrix with a conversion price of $2.20 is a part of the ongoing merger process FRAMINGHAM, Mass., April 21, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulma...
Pulmatrix to merge with Eos Senolytix
Pulmatrix (PULM) and Eos Senolytix, a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases, announced a definitive merger agree...
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan
Combined company to operate as Eos SENOLYTIX, a first-in-class anti-aging biotechnology company $19 million financings to advance lead clinical candidate PTC-2105 for sarcopenia and age-related diseas...
Pulmatrix announces Cullgen terminates merger agreement
Pulmatrix (PULM) announced that on February 28, Cullgen notified Pulmatrix that Cullgen was terminating the Merger Agreement and related transactions thereunder. This termination follows the December ...
Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities
Cullgen had been seeking approval for a merger with Pulmatrix from the China Securities Regulatory Commission and on February 28, 2026, notified Pulmatrix that Cullgen was terminating the Merger Agree...
Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results
Plans to License or Monetize our Migraine and Inhalation Assets Continue FRAMINGHAM, Mass., Feb. 26, 2026 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a biopharmaceut...
Pulmatrix Annual report: Q4 2025
Pulmatrix has published its Q4 2025 annual report on February 26, 2026.
Pulmatrix Earnings release: Q4 2025
Pulmatrix released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Pulmatrix and Cullgen continue to pursue merger
Pulmatrix (PULM) and Cullgen have mutually agreed to waive the “No Solicitation” clause in the Merger Agreement signed in November 2024 in order to permit each party to explore alternate…
Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives
Pulmatrix continues to support Cullgen in seeking approval for their merger from the China Securities Regulatory Commission FRAMINGHAM, Mass. , Dec. 18, 2025 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatri...
Pulmatrix reports Q3 EPS (24c) vs. (71c) last year
Reports Q3 revenue $0 vs. $366,000 last year. Revenue decrease is primarily related to completion of the wind down of the PUR1900 Phase 2b clinical trial during the year ended…
Pulmatrix to potentially divest its patent portfolio for iSPERSE technology
Peter Ludlum, Interim CEO of Pulmatrix (PULM), commented, “Our focus in the third quarter has been to advance steps to complete the proposed merger with Cullgen, a privately held, clinical-stage…